What is HOWL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for HOWL?

P/E (TTM) is n/a and 52-week range is $0.27 to $1.94 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s HOWL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for HOWL?

The company profile lists revenue (TTM) near $21M, net income (TTM) near $4M, EPS (TTM) near $-0.73 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Werewolf Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Watertown, Massachusetts, US, 48.6M shares outstanding, ISIN US95075A1079 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Werewolf Therapeutics Inc

$HOWL

Health Care · Biotechnology

IR Run Scenarios

$0.98

+7.65%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Employees

Website

werewolftx.com/

IPO

2021-04-30

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)